Revelation Biosciences (REVB) to Release Earnings on Friday

Revelation Biosciences (NASDAQ:REVB) is expected to be issuing its quarterly earnings data before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ($3.20) per share for the quarter.

Revelation Biosciences Stock Down 1.4 %

REVB opened at $2.91 on Friday. The stock has a market cap of $2.63 million, a price-to-earnings ratio of -0.01 and a beta of 0.17. Revelation Biosciences has a twelve month low of $2.36 and a twelve month high of $60.80. The company’s 50-day moving average price is $4.40 and its two-hundred day moving average price is $9.11.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.